Great Lakes Advisors LLC Makes New Investment in TG Therapeutics, Inc. $TGTX

Posted by Brenda Bartman on Aug 23rd, 2026

Great Lakes Advisors LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the second quarter, HoldingsChannel reports. The fund bought 20,124 shares of the biopharmaceutical company’s stock, valued at approximately $1,106,000.

Several other large investors also recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of TG Therapeutics during the second quarter worth about $1,211,429,000. Vanguard Group Inc. grew its position in shares of TG Therapeutics by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock valued at $472,220,000 after purchasing an additional 319,703 shares during the period. State Street Corp increased its stake in TG Therapeutics by 4.7% during the 4th quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock worth $252,789,000 after purchasing an additional 379,380 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in TG Therapeutics by 35.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after purchasing an additional 531,759 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in TG Therapeutics by 19.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,747,373 shares of the biopharmaceutical company’s stock worth $58,048,000 after buying an additional 286,325 shares during the period. 58.58% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Bank of America upped their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. B. Riley Financial lifted their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, TG Therapeutics presently has a consensus rating of “Hold” and an average price target of $63.00.

Read Our Latest Stock Report on TGTX

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $54.27 on Friday. TG Therapeutics, Inc. has a 12 month low of $26.76 and a 12 month high of $59.30. The company’s fifty day simple moving average is $53.02 and its 200-day simple moving average is $40.90. The firm has a market cap of $8.31 billion, a PE ratio of 19.81, a P/E/G ratio of 2.33 and a beta of 1.62. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. During the same period last year, the business posted $0.17 EPS. The firm’s revenue for the quarter was up 70.2% on a year-over-year basis. Equities research analysts expect that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

About TG Therapeutics

(Free Report)

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.